Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis
Cancer Medicine · 2023
DOI: 10.1002/cam4.5628 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Pallawi Torka und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Roswell Park Cancer Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, CCR NIH HHS.
Abstract (Originalsprache)
Background
Quantitative methods of Fluorodeoxyglucose Positron Emission Tomography (FDG‐PET) interpretation, including the percent change in FDG uptake from baseline (ΔSUV), are under investigation in lymphoma to overcome challenges associated with visual scoring systems (VSS) such as the Deauville 5‐point scale (5‐PS).
Methods
In CALGB 50303, patients with DLBCL received frontline R‐CHOP or DA‐EPOCH‐R, and although there were no significant associations between interim PET responses assessed centrally after cycle 2 (iPET) using 5‐PS with progression‐free survival (PFS) or overall survival (OS), there were significant associations between central determinations of iPET ∆SUV with PFS/OS. In this patient cohort, we retrospectively compared local vs central iPET readings and evaluated associations between local imaging data and survival outcomes.
Results
Agreement between local and central review was moderate (kappa = 0.53) for VSS and high (kappa = 0.81) for ∆SUV categories (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Roswell Park Cancer Comprehensive Cancer Center, Buffalo, New York, USA.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Radiology, The Ohio State University, Columbus, Ohio, USA.
- Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
- CCS Associates, Inc., San Jose, California, USA.
- Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
ORCID-Profile: Pallawi Torka, Levi D Pederson, Heiko Schöder
Förderung
- NIH HHS
- NCI NIH HHS
- CCR NIH HHS
- National Institutes of Health
- Amgen
- AstraZeneca
- GlaxoSmithKline
- Johnson and Johnson
Zitieren
APA
Torka, P., Pederson, L. D., Knopp, M. V., Poon, D., Zhang, J., Kahl, B. S., Higley, H. R., Kelloff, G., Friedberg, J. W., Schwartz, L. H., Wilson, W. H., Leonard, J. P., Bartlett, N. L., Schöder, H., & Ruppert, A. S. (2023). Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis. Cancer Medicine. https://doi.org/10.1002/cam4.5628
Vancouver
Torka P, Pederson LD, Knopp MV, Poon D, Zhang J, Kahl BS, et al. Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis. Cancer Medicine. 2023. doi:10.1002/cam4.5628
BibTeX
@article{Torka2023,
author = {Torka, Pallawi and Pederson, Levi D and Knopp, Michael V and Poon, David and Zhang, Jun and Kahl, Brad S and Higley, Howard R and Kelloff, Gary and Friedberg, Jonathan W and Schwartz, Lawrence H and Wilson, Wyndham H and Leonard, John P and Bartlett, Nancy L and Schöder, Heiko and Ruppert, Amy S},
title = {Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5628}
}
EUVIMED